primary central nervous system lymphoma
Conditions
Interventions
Experimental group:Orelabrutinib+Rituximab+Methotrexate
Sponsors
Department of lymphoma and plasmacytoma disease,Senior Department of Hematology,the Fifth Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with no previous treatment and pathological diagnosis of primary central diffuse large B-cell lymphoma; 2. Aged 18 to 70 years; 3. Before performing specific operations, sign an informed consent form; 4. At least one measurable lesion; 5. Have adequate organ function, including: blood routine: neutrophils >=1.5x10^9/L, hemoglobin >=80g/L, platelets >=75x10^9/L; total bilirubin 50ml/min; 6. The expected survival period is more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Those who have contraindications to any of the components of the orelabrutinib, rituximab, and methotrexate regimens; 2. History of other malignancies that may affect the compliance of the study protocol or the analysis of the results; 3. Severe cardiac insufficiency; 4. Use other anti-tumor treatments other than this study; 5. Patients known to be HIV-positive; 6. Pregnant or lactating women; 7. There are clinical conditions that other investigators consider unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival rate;Adverse event; | — |
Countries
China
Contacts
Public ContactHuang Wenrong
Department of lymphoma and plasmacytoma disease,Senior Department of Hematology,the Fifth Medical Center of PLA General Hospital
Outcome results
None listed